Results 171 to 180 of about 38,559 (244)

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

Gregorio GD, Basset S, Manmohan H, Nixon WC, Pogaku A, Zhou J, Sanderson DJ, Lengieza ML, Bocchio M.   +8 more
europepmc   +1 more source

Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy. [PDF]

Brain Behav
Ham R, Gardner J, Carter A, Liknaitzky P.   +3 more
europepmc   +1 more source

When the therapist hallucinates: AI, psychedelics, and the risks of unsupervised digital mental health care. [PDF]

Digit Health
MacIntyre MR.
europepmc   +1 more source

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants. [PDF]

Transl Psychiatry
Erne L, Mueller L, Straumann I, Ademaj B, Eckert A, Vukalovic I, Valenta J, Luethi D, Liechti ME, Vogt SB.   +9 more
europepmc   +1 more source

A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry. [PDF]

Cureus
Raza M, Kaur J.
europepmc   +1 more source

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model. [PDF]

ACS Chem Neurosci
Kandilakis CL, Papatheodoropoulos C.
europepmc   +1 more source

Development of a mandarin version of the five dimensional altered states of consciousness (5D-ASC) rating scale. [PDF]

Drug Sci Policy Law
Aday JS, Zong Z, Song J, O'Donovan A, Woolley JD.   +4 more
europepmc   +1 more source

From Science to Pleasure: Justifications of the Use of Classic Psychedelics in Finland. [PDF]

Nordisk Alkohol Nark
Tsupari M, Hupli A.
europepmc   +1 more source

Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis. [PDF]

Harm Reduct J
Argyri EK, Krecké J, Robinson OC, Evans J, Skragge M, Morgan CJA.   +5 more
europepmc   +1 more source